Going forward I share the frustration with everyone here re the timing of the funding but what irritates me is despite many constructive suggestions from knowledgeable posters here and despite our loyalty for some almost a decade with large amounts of shares held between us this company has no intention to take the slightest notice of what they shareholders want.
They see themselves as a institutional friendly company when the nobody else shares that notion.
Their IR efforts are supposed to target big funds yet they have not succeeded despite trying for years.
The offering is done so the way I look at it is now all about damage control meaning let's shift the focus to the retail investors so we can not only convert the new shareholders to long term investors but add more of the same.
Fix that website so it is appealing to investors and present your commercial drugs in an inviting manner.
A soon to be late stage NASH company with promising oncology program and growing sales is valued a fraction of comparable companies with less to offer.
This is wrong and management needs to take their responsibility to put it right rather than being worried about maintaining their multiple six figure income and yearly additional bonuses
I personally feel as shareholder of this company been neglected...